NUVB - Nuvation Bio Inc.

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
3.6 0.2 (5.56%)	---	---	0.0 (0.0%)	0.01 (0.28%)	0.17 (4.71%)	0.03 (0.8%)	0.03 (0.8%)

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: Closed

Earnings & Ratios

Basic EPS:: -0.17
Diluted EPS:: -0.17
Basic P/E:: -22.3529
Diluted P/E:: -22.3529
RSI(14) 1m:: 100.0
VWAP:: 3.8
RVol:: 1.4919

Events

Period	Kind	Movement	Occurred At
1m	Price increase 1m	3.8 +0.04 (+1.2%)	Oct 15 15:53
1m	Price increase 1m	3.77 +0.04 (+1.07%)	Oct 15 15:08
1m	Price increase 1m	3.71 +0.04 (+1.09%)	Oct 15 15:02
1m	Price increase 1m	3.59 +0.05 (+1.56%)	Oct 15 13:34
1m	Price increase 1m	3.68 +0.06 (+1.8%)	Oct 15 12:12